Investigating the effect of Sequential Therapy and Triple Therapy for H-pylori treatment

Phase 2

• Conditions: Helicobacter Pylori.; Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere; B96.81

• Registration Number: IRCT20180131038581N2
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 September 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

Patients who had not previously been treated for H. pylori
Being older than 18 years
Gastrointestinal symptoms such as nausea, vomiting, indigestion and melena
Being a candidate for endoscopy
Not responding to experimental therapy

Exclusion Criteria

Pregnant patients
Lactating patients
Patients with severe heart
Liver disease
Lung disease
Kidney disease
Patients with malignancies
Being allergic to amoxicillin
Being allergic to clarithromycin
Being allergic to tinidazole
Patient's dissatisfaction with participating in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Helicobacter Pylori infection eradication rate. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Urea breath test (UBT).

Secondary Outcome Measures

Name	Time	Method
Mild drug side effects. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Questionnaire, Physician's examination of patient's clinical symptoms.;Severe drug side effects. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Questionnaire, Physician's examination of patient's clinical symptoms.;Drug intolerance. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Questionnaire, Physician's examination of patient's clinical symptoms.